Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adolescent emergency medicine: The Forgotten Tribe.

Archives of disease in childhood·2026

Same author

Upholding Pluralism in Occupational Therapy: A Response to Recent Calls for Political Alignment.

Canadian journal of occupational therapy. Revue canadienne d'ergotherapie·2026

Same author

Utility and limitations of the FDA adverse events reporting system public dashboard for safety analyses: a case study with vesicular monoamine transporter 2 inhibitors.

Expert opinion on drug safety·2025

Same author

Predictors of hippocampal tauopathy in people with and at risk for human immunodeficiency virus infection.

Journal of neurovirology·2023

Same author

Redirecting Nonurgent Patients From the Pediatric Emergency Department to Their Pediatrician Office for a Same-Day Visit-A Quality Improvement Initiative.

Pediatric emergency care·2022

Same author

Frontal lobe microglia, neurodegenerative protein accumulation, and cognitive function in people with HIV.

Acta neuropathologica communications·2022

Search research articles

Related Experiment Video

Updated: May 18, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study.

Michelle Jacobs¹, Pamela S Sherry, Leigh M Taylor

¹Pharmacotherapy Clinic, Lahey Clinic, Burlington, MA, USA. m.jacobs@neu.edu

Journal of the American Pharmacists Association : Japha

|October 2, 2012

Summary

Clinical pharmacists collaborating with physicians significantly improved glucose control, lipid levels, and blood pressure in type 2 diabetes patients. This collaborative approach also increased patient adherence to essential screenings and preventive measures.

Related Experiment Videos

Last Updated: May 18, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Area of Science:

Ambulatory care
Clinical pharmacy
Diabetes management

Background:

Type 2 diabetes requires comprehensive management of glucose, blood pressure, and lipids.
Patient adherence to preventive screenings is crucial for managing diabetes complications.

Purpose of the Study:

To evaluate the impact of clinical pharmacists collaborating with physicians on patient outcomes in type 2 diabetes.
To assess improvements in glycemic control, blood pressure, and lipid profiles.
To determine patient adherence to recommended screenings and preventive measures.

Main Methods:

Prospective, randomized clinical practice study involving 164 patients with type 2 diabetes (A1C > 8%).
Intervention group received care from clinical pharmacists and physicians; control group received standard care.
Pharmacist interventions included medication review, physical assessment, laboratory monitoring, patient counseling, and reinforcement of lifestyle modifications.

Main Results:

The intervention group showed significant improvements in glycosylated hemoglobin (A1C) and low-density lipoprotein (LDL) cholesterol compared to the control group.
Diastolic blood pressure significantly improved in the intervention group.
Patients in the intervention group had higher rates of screening for retinopathy, neuropathy, and microalbuminuria.

Conclusions:

Collaborative diabetes management involving clinical pharmacists enhances overall patient care.
Integrating clinical pharmacists into ambulatory care settings improves key health metrics for type 2 diabetes patients.
Pharmacist collaboration promotes better adherence to preventive care guidelines.